Activation of the ERK1/2 pathway is a key downstream target of BCR signaling and is associated with increased CLL B cells survival, resistance to chemotherapy and upregulation of chemokine secretion [44]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.